Study of Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma
Patients with melanoma can succumb to subclinical metastatic disease, not detectable at
presentation by conventional physical examination, hematologic and biochemical screening, or
radiologic evaluation. More intensive radiologic evaluation with CT or radioisotope scanning
has not proven to be useful. What may be useful is a more sensitive method of staging
melanoma patients at presentation, specifically evaluating them for subclinical systemic
disease.
Observational
Observational Model: Cohort, Time Perspective: Prospective
Assess the sensitivity of RT-PCR to detect evidence of melanoma cells in bone marrow and/or peripheral blood and estimate sensitivity separately for each of the different stage groupings for melanoma
2 years
No
Danile Coit, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
91-125
NCT00588198
October 1991
September 2009
Name | Location |
---|---|
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |